A5092059898- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Liver Disease Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Cancer Genomics and Diagnostics
- Glutathione Transferases and Polymorphisms
- Hormonal Regulation and Hypertension
- Genomics, phytochemicals, and oxidative stress
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Polyomavirus and related diseases
- MicroRNA in disease regulation
- Ovarian cancer diagnosis and treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Adipose Tissue and Metabolism
Peking Union Medical College Hospital
2023-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2023-2025
Shandong First Medical University
2024
Shandong Tumor Hospital
2024
Abstract Notable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC BCLC stage 0-A received 3 $$\times $$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mo>×</mml:mo> </mml:math> Gy SBRT two cycles tislelizumab, an anti-PD-1 monoclonal antibody before curative resection....
Background: Pheochromocytoma and paragangliomas (PPGLs) caused refractory hypertension in clinics. The sustained risk of local or metastatic recurrences new tumor development prompted more research on diagnosis, prognosis prediction, immunotherapy. Method: stemness is closely related to the heterogeneous growth tumor, metastasis, drug-resistance, mRNA expression-based indices (mRNAsi) could reflect stemness. This was calculated based OCLR machine learning algorithm PPGLs patients’ TCGA...
Abstract Homologous recombination deficiency (HRD) testing has been approved by FDA for selecting epithelial ovarian cancer (EOC) patients who may benefit from the first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. However, effects of HRD on clinical outcomes chemotherapy and PARPi therapy have not rigorously evaluated in Chinese EOC patients. Here, we developed an assay applied it to two large retrospectively collected patient cohorts. In adjuvant cohort (FACT, N...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Non-alcohol fatty liver diseases are increasingly becoming a major risk factor of hepatocellular carcinoma (HCC). And accumulating evidence indicates that antioxidants promote tumor growth or metastasis after onset in several cancer types. However, whether can prevent accelerate hepatic tumorigenesis with steatosis remains unknown. In this study, we investigated effects resveratrol (RES) and N-acetylcystein (NAC) on HCC formation setting. both high fat diet (HFD) plus DEN AKT/Ras-induced...
89 Background: A number of similar tests were developed since FDA approval using niraparib in HRD positive (HRD score >=42) patients. However, various factors can substantially influence estimation. We hereby evaluated the concordancy bioinformatics pipelines, especially different copy variation (CNV) algorithms, inferring scores. Methods: total 195 ovarian cancer patients enrolled from April 2021 to Dec 2022 used for retrospective analysis this study. Both tumor tissue and blood samples...